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Chronic Acute Hepatitis
A Review
Klaus .\nselm, M.D.*

The current literature concerning chronic acute hepatitis is reviewed. The clinical
picture, morphology, labcnatory data and etiology are discussed. It is pointed out
that tnuch work is still lo be done toward fully understanding this disease. A program of treatment is suggested.

A group of young women with
chronic liver disease and hypergammaglobulinemia was described by Kunkel
and .Ahrens' in 1951. In the following
years the term chronic active hepatitis(C.-\H) was applied to this entity. The
;ipiv;irance of LE cells was described in
similar groups of patients.-' * It was
then apparent that many of these patients had systemic clinical features
usually not seen in viral hepatitis or cirfhosis. In 1956, Mackay et aF introduced the term "lupoid hepatitis" in
their description of a group of seven
patients and suggested an antigen-antihody reaction was an important ctio'ogic factor in this disease. In a later
'description Mackay" included lupoid
hepatitis in a group of 69 patients with
^AH and put forth the following char^teristics:

3. elevation of serum gamma globulin by 2 to 6 grams.
4. morphologic piecemeal necrosis.
l\niphoid infiltration and fibrosis.
5. various serum aulo-antibody reactions,
6. suppression by immune suppressive drugs in the early stage of
the disease.
Because of the variability of the
clinical and histological picture, chronic
active hepatitis has been described under a variety of names. .\ few examples
are cryptogenic cirrhosis." chronic liver
disease in young women,** plasma cell
hepatitis." progressive hepatitis.'" active
juvenile cirrhosis," subacute hepatitis.'- and auto-immune hepatitis.' -''
Clinical Features

' persistent fluctuating activity for
more than six months.

The term chronic active hepatitis
includes a heterogenous group of patients with a spectrum of disease varying from viral hepatitis to cirrhosis.
However, a past history of viral hepatitis can be obtained in only a small num-

- activity manifested by elevation
of serum transaminases.
'^'^lon of Gastroenterology
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ber of patients.' - The age of onset
ranges from the first to the seventh decade, but the majority of patients are
first seen in their early teens or twenties.""'* There is a predominance of
female over male patients" ' ' and a
role for estrogens has been suggested
in the pathogenesis of this disease.
Jaundice and insidiously developing
fatigue are predcmiinant clinical symptoms.'' often accompanied by low
grade fever, anorexia and malaise. Systemic involvement is frequent. Maclachlan'"' observed arthralgias and
arthritis in 16 of a group of 20 patients
with CAH. There was involvement of
the heart in three and of the lungs in
five. Other systemic complications included generalized lymphadenopathy,
glomerulonephritis, generalized convulsions, ulcerative colitis, leucopenia.
thrombocytopenia, and urticaria. Similar observations were made by other
authors ' '' The liver is usuallyfirmand
tender, and the spleen is frequently enlarged. Spider angiomata are noted
with ascites in 3()'~^ of observed
cases.'^

4. CAH in young women with a
higher incidence of systerr c
manifestations, including positi e
LE cell preparations, butterrly
rash, pleurisy and hemolv ic
anemia. This group of patients
led to the use of the term "lupoid hepatitis."-'" There has been
considerable controversy whether
these patients constitute a separate entity.'^
Laboratory Findings
Levels of transaminases usually
lluctuate widely," the alkaline phosphatase is generally elevated'^ while the
bilirubin may be normal. SchafTner and
Klion'' found it hard to correlate these
laboratory data with the clinical picture and the morphology of the liver
Most impressive is the elevation of the
gamma globulins,""' ' - " ''' appai . ntl\
with IgG as the main contributor."""
IgM may be moderately increased,""
while measurements of IgA may range
from a decreased level'""* to a menderate increase.'" Patients with a positive
antinuclear factor tend to have a more
significant increase of IgM.
Positive LE preparations and antinuclear factor are found frequently as
expressions of nonspecific antigen-antibody reactions. Maclachlan'-' reported
positive LE cells in 14 of 19 patient^
and positive homogenous antinuclear
factor in 16 of 18 patients. Mackay and
Wood-" observed positive LE cells in
22 of 72 patients. Mackay et al* a''
tempted to separate lupoid hepauii^
from CAH. They found 10% posit'^'
homogenous antinuclear factor a"^
30% positive speckled antinuvlei-'

Four variants were suggested by
SchafTncr and Klion.'' althmigh all are
understood to represent the same disease;
1 C'.\H iKcurring in postmenopau-.il ^vomen. with a more rapid
and progressive course towards
cirrhosis and death.
2. C.-\H m young girls near puberty
with associated menstrual abnormalities and a marked sensitivity to estrogens.
3. CAH in prepubertal boys with a
more rapidly progressive course
than in girls of a similar age
group.

factor in chronic active hepatitis
contrasted with 32% positive hom^"
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genous and 4 1 % positive speckled antinuclear factor in lupoid hepatitis.
False positive serologic tests for syphilid have also been reported.'"'
Specific circulating antibodies against
the individual liver cell have never been
rei irted," '^ although antibodies directed against proliferating bileduct cells
h. been observed.-' Non-organ-specific antibodies directed against mitochondria, present in virtually all patients with primary bUiary cirrhosis,
were found in 28% of patients with
CAH;-- smooth muscle antibodies were
found in 48% of CAH;-' antibodies
to cytoplasmic antigens in 12 of 15
patients.-*

through macrophages. These
cells contain gammaglobulin,
demonstrable by immunofluorescence, and are thought to be the
cause of the hypergammaglobulinemia-'
(immunocytes).
4. Active regeneration with multinucleation of hepatocytes and
nodule formation.
Etiology

Pathology
Four pathologic processes take place
in chronic active hepatitis, all closely
linked, though one might predominate:
1. Necrosis of individual liver cells
al the periphery of the liver lobule
with subsequent destruction of
the limiting end plate.-'
(Electron microscopic changes
varying from cell to cell: focal
cytoplasmic degeneration, hypertrophy and vesiculation of the
endoplasmic reticulum and shedding of the cytoplasm from the
sinusoidal surface.'-'')
2. Active fibroplasia around damaged liver cells with newly formed capillaries, proliferating bile
ducts and septal formation by
fibroblasts eventually leading to
cirrhosis.-'
^- Accumulation of mononuclear
cells deriving from the reticuloendothelial system after transition
197

The cause of chronic active hepatitis is not known and it is probable that
this disease has several etiologic components. Disturbances of hepatic circulation, malnutrition and genetic factors
have been considered. Mackay"--" believes that CAH represents the result
of liver damage caused by viruses in
persons with abnormal immune tolerance, particularly those with the tendency to respond abnormally to the release of liver cell compounds. The
autoimmune response then is perpetuated because immunocytes continue to
be stimulated by antigen from damaged
liver cells. Evidence against this theory
is the absence of demonstrable antibodies against hepatocytes."' ' Popper-"
does not believe in autoimmunity by
direct action of circulating antibodies.
He suggests that the autoimmune process is initiated by complexes between
antibodies and antigens, not necessarily hepatic and that they are responsible for perpetuation of the process.
The systemic features, often resembling
systemic lupus erythematosis, arc
caused by the same circulating antigen-antibody complexes. Not understood is the frequent occurrence of
CAH leading to cirrhosis in patients
with congenital agammaglobulinemia.

Anselm
Therapy
No specific therapy against CAH is
available. Results of therapy are diflficult to assess and controlled clinical
trials are few in number. It is important
to realize that therapy should not be
guided by the morphology of liver biopsies nor by laboratory tests, but by the
symptoms and clinical appearance of
the patient. Immunosuppressive agents
(steroids, Azathioprine, 6-Mercaptopurine) will improve BSP excretion-**
and will reduce the gammaglobulin,
transaminase, and bilirubin levels.'"-^o'" '-' However, this therapy may not delay the inexorable progress of the disease to cirrhosis and death.
A suggested course of management-"
includes: Activity and diet directed by
the patient's symptoms; complications
treated symptomatically in the usual
fashion. More severe symptoms may
respimd to Prednisone, started at 60
mg daily (single dose) and gradually
reduced over several months to 10-20
mg daily. If symptoms cannot be controlled, a trial with Azathioprine should

be attempted, 50-150 mg daily. Occasionally the combination of 5-10 mg of
Prednisone with 25-50 mg of AzathiO'
princ has been beneficial.
Prognosis
The natural history of chronic active
hepatitis progresses to the complication
of portal hypertension and hypersplenism. The disease course is fluctuaiing
but progressive and many patients die
from hepatic failure and from bleeding
esophageal varices. Mortality also occurs from associated complication^ including ulcerative colitis, septicemia,
pyelonephritis and glomerulonephritis.
The average survival from the time of
diagnosis ranges from four to srven
years."-''' Although the ultimate prognosis of CAH is guarded, an occasional
patient maintains symptomatic good
health over a long period of time in
spite of laboratory evidence of severe
liver disease. If the prognosis of CAH
is to be more hopeful, fundamental
knowledge is necessary in the etiolog}
and pathogenesis of this disease.
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